本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

BridgeBio Pharma, Inc.

54.36
-1.8950-3.37%
盤後54.360.00000.00%19:53 EDT
成交量:119.18萬
成交額:6,532.88萬
市值:103.92億
市盈率:-13.28
高:56.50
開:56.21
低:54.29
收:56.26
52周最高:57.49
52周最低:21.72
股本:1.91億
流通股本:1.51億
量比:0.67
換手率:0.79%
股息:- -
股息率:- -
每股收益(TTM):-4.0935
每股收益(LYR):-2.8793
淨資產收益率:-1789.67%
總資產收益率:-41.96%
市淨率:-5.81
市盈率(LYR):-18.88

資料載入中...

2023/11/22

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/11/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/11/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/11/02

重要事件披露

Form 8-K - Current report
2023/11/02

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/09/25

重要事件披露

Form 8-K - Current report
2023/09/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/03

重要事件披露

Form 8-K - Current report
2023/08/03

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/07/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/07/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/07/17

重要事件披露

Form 8-K - Current report
2023/06/23

重要事件披露

Form 8-K - Current report
2023/05/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/05/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/05/04

重要事件披露

8-K - Current report
2023/05/04

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans